UK-based artificial intelligence (AI) company Brainomix got FDA approval for its latest product, the 360 e-Lung system, after successfully completing its phase II trial. The Brainomix 360 e-Lung system is designed to identify interstitial lung diseases (ILDs), which are more than 200 diseases. It examines CT scans to quantify pulmonary fibrosis and other features using